Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Exp Dermatol. 2017 Mar 8;26(8):697–704. doi: 10.1111/exd.13260

Figure 1. Interleukin (IL)-6 augments epidermal expression of transforming growth factor-β type I and II receptor (TGF-βRI and II).

Figure 1

Punch biopsies (4mm) obtained from wild type (A-I.) or transgenic IL-6 over-expressing mice (A-II.) were formalin-fixed, and paraffin-embedded for histology. IL-6 KO keratinocytes were treated with 0ng/ml (A-III) or 10ng/ml (A-IV) IL-6 for 16 hours, then fixed with paraformaldehyde. Slides were stained with monoclonal anti-TGF-βRII (red) followed by Alexafluor 546 conjugated secondary antibodies and DAPI (blue) counterstain. Slides were visualized at 20X objective. (B) Ker-CTs were cultured and treated as described. Treatments indicated as ng/ml of IL-6-TGF-β1. Expression of TGF-βRI and II mRNA were determined by SYBR Green real-time PCR. Data are expressed as percent negative control of average CT fold change ± percent SEM (*= p< 0.05, n=3 cultures per data point). (C-D) Ker-CTs were cultured as described, treated with IL-6 neutralizing antibody and +/− IL-6. Flow cytometry for TGF-βRI and II was performed and histograms for each are presented. (C) TGF-βRI (D) TGF-βRII.